Evaluation of Three Different Methods to Prevent Dialyzer Clotting Without Causing Systemic Anticoagulation Effect

Artificial Organs

Volumn 35, Issue 1, 2011, Pages 83-88

  Richtrova, Pavlina ^a   Rulcova, Kamila ^a   Mares, Jan ^a   Reischig, Tomas ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Anticoagulation; Biocompatibility; Dialysis; Thrombogenicity

Indexed keywords

ARTIFICIAL ORGANS; CHEMICAL ACTIVATION; DIALYSIS; HEMODIALYZERS; PLATELETS;

ANTI-COAGULATION; ANTI-THROMBIN COMPLEXES; ARTIFICIAL MATERIAL; COMPLEX PRODUCTION; EXTRACORPOREAL CIRCUITS; HAEMODIALYSIS; PLASMA CONCENTRATION; PLATELET FACTOR-4; PROSPECTIVES; THROMBOGENICITY;

BIOCOMPATIBILITY;

CITRIC ACID; SODIUM CHLORIDE; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; BLOOD CLOTTING; CLINICAL ARTICLE; COMPARATIVE STUDY; CROSSOVER PROCEDURE; EVALUATION; EXTRACORPOREAL CIRCULATION; FEMALE; HEMODIALYSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOGENICITY;

EID: 78651460837     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2010.01038.x     Document Type: Article

References (16)

1. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG. The effects of heparin and low molecular weight heparins on bone. Thromb Res 2008;122:293-8.
2. Wiemer J, Scherberich JE. When lipids increase in dialysis: the role of heparin! Standard heparin increases, low-molecular-weight heparin lowers triglycerides. MMW Fortschr Med 1999;141:29-32.
3. Murray PT, Hursting MJ. Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis. Ren Fail 2006;28:537-9.
4. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section V. Chronic intermittent hemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant 2002;17 (Suppl. 7):63-71.
5. Chanard J, Lavaud S, Paris B, et al. Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. Preclinical studies. ASAIO J 2005;51:342-7.
6. Schwab SJ, Onorato JJ, Sharar LR, Dennis PA. Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding. Am J Med 1987;83:405-10.
7. Richtrova P, Opatrny K Jr, Vit L, Sefrna F, Perlik R. The AN69 ST hemodialysis membrane under conditions of two different extracorporeal circuit rinse protocols-a comparison of thrombogenicity parameters. Nephrol Dial Transplant 2007;22:2978-84.
8. Erlenkötter A, Endres P, Nederlof B, Hornig C, Vienken J. Score model for the evaluation of dialysis membrane hemocompatibility. Artif Organs 2008;32:962-9.
9. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr Opin Nephrol Hypertens 2003;12:593-8.
10. Lavaud S, Paris B, Maheut H, et al. Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J 2005;51:348-51.
11. Lavaud S, Canivet E, Wuillai A, et al. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Nephrol Dial Transplant 2003; 18:2097-104.
12. Chanard J, Lavaud S, Maheut H, Kazes I, Vitry F, Rieu P. The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Nephrol Dial Transplant 2008;23:2003-9.
13. Evenepoel P, Dejagere T, Verhamme P, et al. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis 2007;49:642-9.
14. Andrassy K, Ritz E, Bommer J. Effects of hemodialysis on platelets. Contrib Nephrol 1987;59:26-34.
15. Gritters M, Grooteman MP, Schoorl M, et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during hemodialysis. Nephrol Dial Transplant 2006;21:153-9.
16. Kozik-Jaromin J, Nier V, Heemann U, Kreymann B, Böhler J. Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation. Nephrol Dial Transplant 2009;24:2244-51.